Research on consumer staples sector companies including food, beverages, and household products.
5 articles in Consumer Staples
General Mills’ Q4 FY2026 adjusted EPS beat consensus by 15.9% and the company launched a $3B cumulative cost savings program — both buried under a $2.1B non-cash goodwill impairment. The real business is inflecting positively; the GAAP headline is accounting noise.
Kraft Heinz's 7.1% dividend yield is pricing in a cut that 1.9x free cash flow coverage doesn't support. New CEO Steve Cahillane's $600M investment cycle follows the same playbook that worked at Kellogg's.
Conagra's 11% dividend yield is pricing in a B&G Foods-style halving — but Conagra runs at 3.8x leverage versus B&G's 6-8x, and Q3 organic sales just returned to growth led by Frozen and Snacks.
Altria has re-rated 27% to ~$72, yet still trades at 13x against a 19x historical average while consensus prices three demonstrably wrong calls: a "volume cliff" offset by relentless pricing power, a smoke-free option marked near zero after NJOY, and a ~$9B ABI stake buried by single-multiple math. Forensic case: BUY, $82 in 12 months, $95+ long-term.
Hershey trades at 19x forward earnings versus a 10-year median of 26x, while consensus prices in three demonstrably wrong assumptions about cocoa, GLP-1s, and Salty Snacks. The forensic case points to $235 in 12 months and $275+ longer term. Option 2 — Contrarian hook The market thinks GLP-1s will hurt chocolate demand — peer-reviewed Cornell data shows the opposite. Combined with the cocoa hedge lag and an unmodeled Salty Snacks asset, Hershey's mispricing is measurable, falsifiable, and worth 25%+ upside.
Forensic equity research on US stocks. No spam, unsubscribe anytime.